Country: United States
Language: English
Source: NLM (National Library of Medicine)
TORSEMIDE (UNII: W31X2H97FB) (TORSEMIDE - UNII:W31X2H97FB)
Physicians Total Care, Inc.
TORSEMIDE
TORSEMIDE 20 mg
ORAL
PRESCRIPTION DRUG
DEMADEX is indicated for the treatment of edema associated with congestive heart failure, renal disease, or hepatic disease. Use of torsemide has been found to be effective for the treatment of edema associated with chronic renal failure. Chronic use of any diuretic in hepatic disease has not been studied in adequate and well-controlled trials. DEMADEX is indicated for the treatment of hypertension alone or in combination with other antihypertensive agents. DEMADEX is contraindicated in patients with known hypersensitivity to DEMADEX or to sulfonylureas. DEMADEX is contraindicated in patients who are anuric.
DEMADEX for oral administration is available as white, scored tablets containing 10 mg, 20 mg of torsemide. The tablets are supplied in: 10 mg Bottles of 30 NDC 54868-3835-0 20 mg Bottles of 10 NDC 54868-4687-1 20 mg Bottles of 30 NDC 54868-4687-0 20 mg Bottles of 90 NDC 54868-4687-3 20 mg Bottles of 100 NDC 54868-4687-2 Each tablet is debossed on the scored side with the logo BM and 102, 103, 104, or 105 (for 5 mg, 10 mg, 20 mg, or 100 mg, respectively). On the opposite side, the tablet is debossed with 5, 10, 20, or 100 to indicate the dose. Storage Store at 15° to 30°C (59° to 86°F). Rx only
New Drug Application
DEMADEX - TORSEMIDE TABLET PHYSICIANS TOTAL CARE, INC. ---------- DEMADEX (TORSEMIDE) TABLETS DESCRIPTION DEMADEX (torsemide) is a diuretic of the pyridine-sulfonylurea class. Its chemical name is 1- isopropyl-3-[(4-_m_-toluidino-3-pyridyl) sulfonyl]urea and its structural formula is: Its empirical formula is C H N O S, its pKa is 7.1, and its molecular weight is 348.43. Torsemide is a white to off-white crystalline powder. The tablets for oral administration also contain lactose NF, crospovidone NF, povidone USP, microcrystalline cellulose NF, and magnesium stearate NF. CLINICAL PHARMACOLOGY Mechanism of Action Micropuncture studies in animals have shown that torsemide acts from within the lumen of the thick ascending portion of the loop of Henle, where it inhibits the Na /K /2CI -carrier system. Clinical pharmacology studies have confirmed this site of action in humans, and effects in other segments of the nephron have not been demonstrated. Diuretic activity thus correlates better with the rate of drug excretion in the urine than with the concentration in the blood. Torsemide increases the urinary excretion of sodium, chloride, and water, but it does not significantly alter glomerular filtration rate, renal plasma flow, or acid-base balance. Pharmacokinetics and Metabolism The bioavailability of DEMADEX tablets is approximately 80%, with little intersubject variation; the 90% confidence interval is 75% to 89%. The drug is absorbed with little first-pass metabolism, and the serum concentration reaches its peak (C ) within 1 hour after oral administration. C and area under the serum concentration-time curve (AUC) after oral administration are proportional to dose over the range of 2.5 mg to 200 mg. Simultaneous food intake delays the time to C by about 30 minutes, but overall bioavailability (AUC) and diuretic activity are unchanged. Absorption is essentially unaffected by renal or hepatic dysfunction. The volume of distribution of torsemide is 12 liters to 15 liters in normal adults or in patients with mild to Read the complete document